Smokers more likely to experience vision loss

News
Article

Research indicates smoking increases risk of AMD, cataracts and glaucoma

A no smoking sign hanging on a wall. ©stock.adobe.com – generated with Firefly AI

National No Smoking Day is on Wednesday 13 March in the UK. ©stock.adobe.com – generated with Firefly AI

The risks associated with smoking are not limited to increased risks of cancer and heart disease. Smoking also can be detrimental to vision. In fact, smokers are more likely to experience visual loss, according to a press release issued by Moorfields Eye Hospital, London, in anticipation of National No Smoking Day on Wednesday 13 March in the UK.

Consultant ophthalmologist Mr Luke Nicholson, who leads the medical retina services at Moorfields Eye Hospital, flags the increased associated risks with age-related macular degeneration (AMD).

Eye care providers at Moorfields state that more public awareness is needed regarding the risks associated with smoking and sight loss, because less is known about the effects of smoking on ocular health.

According to Mr Nicholson, “In my role, I have seen the negative impact that smoking has on patients. Quitting smoking brings clear benefits to our health but also protects our retina from developing some irreversible diseases and safeguards our vision.”

Research shows that smoking has been associated with increasing the risk of developing AMD, cataracts and glaucoma.

AMD is the most common cause of sight loss in the UK. If patients already have some form of AMD, research indicates that smoking may also be associated with progression to more advanced forms of the disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.